中文版 | English

在结果中检索

CCPortal

浏览/检索结果: 共4条，第1-4条 帮助

限定条件        
已选(0)清除 条数/页：   排序方式：
Improved symptoms following bumetanide treatment in children aged 3−6 years with autism spectrum disorder: a randomized, double-blind, placebo-controlled trial 期刊论文
Science Bulletin, 2021, 卷号: 66, 期号: 15
作者:  Dai Y.;  Zhang L.;  Yu J.;  Zhou X.;  He H.;  Ji Y.;  Wang K.;  Du X.;  Liu X.;  Tang Y.;  Deng S.;  Langley C.;  Li W.-G.;  Zhang J.;  Feng J.;  Sahakian B.J.;  Luo Q.;  Li F.
收藏  |  浏览/下载：17/0  |  提交时间：2021/09/01
Autism spectrum disorder  Bumetanide  Children  GABA  RCT  
High content anion (S/Se/P) doping assisted by defect engineering with fast charge transfer kinetics for high-performance sodium ion capacitors 期刊论文
Science Bulletin, 2021
作者:  Deng X.;  Zou K.;  Momen R.;  Cai P.;  Chen J.;  Hou H.;  Zou G.;  Ji X.
收藏  |  浏览/下载：26/0  |  提交时间：2021/09/01
Anion doping  Charge transfer kinetics  Sodium ion capacitors  Titanium dioxide  Vacancy engineering  
Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP) 期刊论文
Science Bulletin, 2021, 卷号: 66, 期号: 15
作者:  Ji L.;  Song W.;  Fang H.;  Li W.;  Geng J.;  Wang Y.;  Guo L.;  Cai H.;  Yang T.;  Li H.;  Yang G.;  Li Q.;  Liu K.;  Li S.;  Liu Y.;  Shi F.;  Li X.;  Gao X.;  Tian H.;  Ji Q.;  Su Q.;  Zhou Z.;  Wang W.;  Zhou Z.;  Li X.;  Xu Y.;  Ning Z.;  Cao H.;  Pan D.;  Yao H.;  Lu X.;  Jia W.
收藏  |  浏览/下载：39/0  |  提交时间：2021/09/01
Carfloglitazar  Chiglitazar  Glycemic control  Insulin resistance  PPAR pan-agonist  Type 2 diabetes  
Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS) 期刊论文
Science Bulletin, 2021, 卷号: 66, 期号: 15
作者:  Jia W.;  Ma J.;  Miao H.;  Wang C.;  Wang X.;  Li Q.;  Lu W.;  Yang J.;  Zhang L.;  Yang J.;  Wang G.;  Zhang X.;  Zhang M.;  Sun L.;  Yu X.;  Du J.;  Shi B.;  Xiao C.;  Zhu D.;  Liu H.;  Zhong L.;  Xu C.;  Xu Q.;  Liang G.;  Zhang Y.;  Li G.;  Gu M.;  Liu J.;  Yuan G.;  Yan Z.;  Yan D.;  Ye S.;  Zhang F.;  Ning Z.;  Cao H.;  Pan D.;  Yao H.;  Lu X.;  Ji L.
收藏  |  浏览/下载：39/0  |  提交时间：2021/09/01
Chiglitazar  Glycemic control  Insulin resistance  PPAR pan-agonist  Type 2 diabetes